IVXA-12 is under clinical development by Icosavax and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IVXA-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IVXA-12 overview
IVXA-12 is under development for the prevention of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) infections. It constitutes stabilized prefusion F proteins for each of RSV and hMPV. It is a bivalent vaccine and is being developed based on virus-like article (VLP) technology. It is administered through intramuscular route as a form of suspension.
Icosavax overview
Icosavax, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes vaccines for life-threatening infectious diseases. The company’s pipeline products include a bivalent vaccine candidate, IVX-A12, designed to target respiratory syncytial virus (RSV); and IVX-121, a vaccine candidate designed to target human metapneumovirus (hMPV). Icosavax is also developing vaccines for targeting the viral causes of pneumonia including influenza and SARS-CoV-2 (COVID-19). The company leverages virus-like particle (VLP) platform technology that enables multivalent, particle-based display of complex viral antigens for broad, robust, and durable protection against targeted viruses. Icosavax is headquartered in Seattle, Washington, the US.
For a complete picture of IVXA-12’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
